Chitosan based mucoadhesive nanoparticles of ketoconazole for bioavailability enhancement: Formulation, optimization, in vitro and ex vivo evaluation

Drug Development and Industrial Pharmacy

Volumn 39, Issue 4, 2013, Pages 540-547

  Modi, Jigar ^a   Joshi, Garima ^a   Sawant, Krutika ^a  

^a M S UNIVERSITY OF BARODA   (India)

Author keywords

Chitosan; Ex vivo; Ionic gelation; Ketoconazole; Nanoparticles

Indexed keywords

CHITOSAN; CROSS LINKING REAGENT; KETOCONAZOLE; MUCIN; NANOCARRIER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CROSS LINKING; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DIFFUSION; EX VIVO STUDY; GELATION; IN VITRO STUDY; MALE; NONHUMAN; PARTICLE SIZE; RAT; SIMULATION; STOMACH CONTENT; STOMACH EMPTYING; STOMACH MUCOSA; THERMOGRAPHY; ZETA POTENTIAL;

ANIMALS; ANTIFUNGAL AGENTS; BIOLOGICAL AVAILABILITY; CHITOSAN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; ESOPHAGUS; GASTRIC MUCOSA; KETOCONAZOLE; MALE; NANOPARTICLES; PARTICLE SIZE; RABBITS;

EID: 84874496609     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.666978     Document Type: Article

References (38)

1. Khan Z, Gyanchandani A (1998). Candidiasis-A Review. Proc Indian Natl Sci Acad B, 64:1-34.
2. Walsh TJ, Merz WG. (1986). Pathologic features in the human alimentary tract associated with invasiveness of Candida tropicalis. Am J Clin Pathol, 85:498-502. (Pubitemid 16052960)
3. Mimidis K, Papadopoulos V, Margaritis V, Tomopoulos K, Gatopoulou A, Nikolopoulou V et al. (2005). Predisposing factors and clinical symptoms in HIV-negative patients with Candida oesophagitis: are they always present? Int J Clin Pract, 59:210-213. (Pubitemid 40331223)
4. Martindale (2002). Te Complete Drug Reference. (33rd ed). London: Pharmaceutical press, 389-390.
5. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. (1994). Biodegradable long-circulating polymeric nanospheres. Science, 263:1600-1603. (Pubitemid 24128361)
6. Alonso MJ. (2004). Nanomedicines for overcoming biological barriers. Biomed Pharmacother, 58:168-172. (Pubitemid 38479921)
7. Florence AT, Hillery AM, Hussain N, Jani PU. (1995). Nanoparticles as carriers for oral peptide absorption: studies on particle uptake and fate. J Control Release, 36:39-46.
8. Chen H, Langer R. (1998). Oral particulate delivery: status and future trends. Adv Drug Deliv Rev, 34:339-350. (Pubitemid 28535119)
9. Kawashima Y. (2001). Nanoparticulate systems for improved drug delivery. Adv Drug Deliv Rev, 47:1-2. (Pubitemid 32209228)
10. Andrews GP, Laverty TP, Jones DS. (2009). Mucoadhesive polymeric platforms for controlled drug delivery. Eur J Pharm Biopharm, 71:505-518.
11. Woolfson AD, Elliott GR, Gilligan CA, Passmore CM. (1999). Design of an intravaginal ring for the controlled delivery of 17 beta-estradiol as its 3-acetate ester. J Control Release, 61:319-328. (Pubitemid 29413026)
12. Arbós P, Campanero MA, Arangoa MA, Renedo MJ, Irache JM. (2003). Infuence of the surface characteristics of PVM/MA nanoparticles on their bioadhesive properties. J Control Release, 89:19-30. (Pubitemid 36412111)
13. Janes KA, Calvo P, Alonso MJ. (2001). Polysaccharide colloidal particles as delivery systems for macromolecules. Adv Drug Deliv Rev, 47:83-97. (Pubitemid 32209234)
14. Arias JL, López-Viota M, Gallardo V, Adolfna Ruiz M. (2010). Chitosan nanoparticles as a new delivery system for the chemotherapy agent tegafur. Drug Dev Ind Pharm, 36:744-750.
15. Damge C, Michel C, Aprahamian M, Couvreur P, Devissaguet JP. (1990). Nanocapsules as carriers for oral peptide delivery. J Control Release, 13:233-239. (Pubitemid 20313521)
16. Peng X, Zhang L, Kennedy JF. (2006). Release behaviour of microspheres from cross-linked N-methylated chitosan encapsulated ofoxacin. Carbohydr polym, 65:288-295. (Pubitemid 44142093)
17. Kim S, Lee J. (2011). Folate-targeted drug-delivery systems prepared by nano-comminution. Drug Dev Ind Pharm, 37:131-138.
18. Lin A, Chen J, Liu Y, Deng S, Wu Z, Huang Y et al. (2009). Preparation and evaluation of N-caproyl chitosan nanoparticles surface modifed with glycyrrhizin for hepatocyte targeting. Drug Dev Ind Pharm, 35:1348-1355.
19. Palmeira-de-Oliveira R, Palmeira-de-Oliveira A, Gaspar C, Silvestre S, Martinez-de-Oliveira J, Amaral MH, Breitenfeld L. (2011). Sodium Tripolyphosphate: An excipient with intrinsic in vitro anti-Candida activity, Int J Pharm 421:130-134.
20. Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. (1997). Novel hydrophilic chitosan-polyethylene oxide Nanoparticles as protein carriers. J App Polymer Sci, 63:125-132. (Pubitemid 127613982)
21. Agnihotri SA, Aminabhavi TM. (2007). Chitosan nanoparticles for prolonged delivery of timolol maleate. Drug Dev Ind Pharm, 33:1254-1262. (Pubitemid 350208731)
22. Yin Y, Chen D, Qiao M, Lu Z, Hu H. (2006). Preparation and evaluation of lectin-conjugated PLGA nanoparticles for oral delivery of thymopentin. J Control Release, 116:337-345. (Pubitemid 44827411)
23. Washington N, Washington C, Wilson, CG. (2003). Biological barriers to drug absorption in: Physiological Pharmaceutics, 2nd edition, London: Taylor and Francis, 94-95.
24. Magenheim B, Levy MY, Benita S. (1993). A new in-vitro technique for the evaluation of drug release profle from colloidal carriers-ultraflteration at low pressure. Int J Pharm, 94:115-123. (Pubitemid 23204057)
25. Joseph NM, Sharma PK. (2007). Cross-linked nanoparticles of cytarabine: encapsulation, storage and in-vitro release. Afr J Pharm Pharmacol, 1:11-13.
26. Peppas NA, Ritger PL. (1987). A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. J Control Release, 5:37-42. (Pubitemid 17106644)
27. Yin Y, Chen D, Qiao M, Wei X, Hu H. (2007). Lectin-conjugated PLGA nanoparticles loaded with thymopentin: ex vivo bioadhesion and in vivo biodistribution. J Control Release, 123:27-38. (Pubitemid 47444385)
28. Malhotra M, Kulamarva A, Sebak S, Paul A, Bhathena J, Mirzaei M et al. (2009). Ultrafne chitosan nanoparticles as an efcient nucleic acid delivery system targeting neuronal cells. Drug Dev Ind Pharm, 35:719-726.
29. Ajun W, Yan S, Li G, Huilli L. (2009). Preparation of aspirin and probucol in combination loaded chitosan nanoparticles and in vitro release study. Carbohydr Polym, 75:566-574. (Pubitemid 50290932)
30. Zhang H, Oh M, Allen C, Kumacheva E. (2004). Monodisperse chitosan nanoparticles for mucosal drug delivery. Biomacromolecules, 5:2461-2468. (Pubitemid 39585302)
31. Wu Y, Yang W, Wang C, Hu J, Fu S. (2005). Chitosan nanoparticles as a novel delivery system for ammonium glycyrrhizinate. Int J Pharm, 295:235-245. (Pubitemid 40558806)
32. Papadimitriou S, Bikiaris D, Avgoustakis K, Karavas E, Georgarakis M. (2008). Chitosan nanoparticles loaded with dorzolamide and pramipexole. Carbohydr Polym, 73:44-54.
33. Pan Y, Li Y, Zhao H, Zheng J, Xu H, Wei G, Hao JS, Fu C. (2002) Bioadhesive polysaccharide in protein delivery system: Chitosan nanoparticles improve the absorption of insulin in vivo. Int J Pharm, 249:139-147. (Pubitemid 35333440)
34. Hariharan S, Bhardwaj V, Bala I, Sitterberg J, Bakowsky U, Ravi Kumar MN. (2006). Design of estradiol loaded PLGA nanoparticulate formulations: a potential oral delivery system for hormone therapy. Pharm Res, 23:184-195. (Pubitemid 43214675)
35. Capra RH, Baruzzi AM, Quinzani LM, Strumia MC. (2007). Rheological, dielectric and difusion analysis of mucin/carbopol matrices used in amperometric biosensors. Sensors and Actuator B:Chemical, 124:466-476. (Pubitemid 46874035)
36. Dubernet C. (1995). Termoanalysis of microspheres. Termochim Acta, 248:259-269.
37. Lehr CM, Bouwstra JA, Schacht EH, Junginger HE. (1992). In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int J Pharm, 78:43-48.
38. Bernkop-Schnürch A, Weithaler A, Albrecht K, Greimel A. (2006). Tiomers: preparation and in vitro evaluation of a mucoadhesive nanoparticulate drug delivery system. Int J Pharm, 317: 76-81. (Pubitemid 43866341)